Structure-activity relationships of 4-position diamine quinoline methanols as intermittent preventative treatment (IPT) against plasmodium falciparum

Journal of Medicinal Chemistry

Volumn 54, Issue 18, 2011, Pages 6277-6285

  Milner, Erin ^a   Gardner, Sean ^a   Moon, Jay ^a   Grauer, Kristina ^a   Auschwitz, Jennifer ^a   Bathurst, Ian ^d   Caridha, Diana ^a   Gerena, Lucia ^a   Gettayacamin, Montip ^b   Johnson, Jacob ^a   Kozar, Michael ^a   Lee, Patricia ^a   Leed, Susan ^a   Li, Qigui ^a   McCalmont, William ^a   Melendez, Victor ^a   Roncal, Norma ^a   Sciotti, Richard ^a   Smith, Bryan ^a   Sousa, Jason ^a   Tungtaeng, Anchalee ^b   Wipf, Peter ^c   Dow, Geoffrey ^a   more..

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b U S ARMY   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d International Center Cointrin   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2,8 BIS(TRIFLUOROMETHYL)QUINOLIN 4 YL] 2 [2 (CYCLOPROPYLAMINO)ETHYLAMINO]ETHANOL; ANTIMALARIAL AGENT; MEFLOQUINE; UNCLASSIFIED DRUG; WR 621308;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG INTERMITTENT THERAPY; DRUG PENETRATION; MALARIA FALCIPARUM; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMALARIALS; CELL LINE; CELL MEMBRANE PERMEABILITY; DIMERIZATION; DOGS; DRUG RESISTANCE; ETHANOLAMINES; ETHYLENEDIAMINES; MALARIA; MEFLOQUINE; METHANOL; MICE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; QUINOLINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052786962     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200647u     Document Type: Article

References (16)

1. Dow, G. S.; Magill, A. J.; Ohrt, C. Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki Ther. Clin. Risk Manage. 2008, 4
2. Briand, V.; Bottero, J; Noël, H.; Masse, V.; Cordel, H.; Guerra, J.; Kossou, H.; Fayomi, B.; Ayemonna, P.; Fievet, N.; Massougbodji, A.; Cot, M. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine J. Infect. Dis. 2009, 200, 991-1001
3. McGready, R. Intermittent preventive treatment of infants with mefloquine reduces risk of clinical malaria in areas of moderate malaria transmission and high resistance to sulphadoxine-pyrimethamine, but safety and tolerability issues need consideration Evidence-Based Med. 2010, 15, 71-72
4. Milner, E.; McCalmont, W.; Bhonsle, J.; Caridha, D.; Cobar, J.; Gardner, S.; Gerena, L.; Goodine, D.; Lanteri, C.; Melendez, V.; Roncal, N.; Sousa, J.; Wipf, P.; Dow, G. Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols Malar. J. 2010, 9, 51
5. Milner, E.; McCalmont, W.; Bhonsle, J.; Caridha, D.; Carroll, D.; Gardner, S.; Gerena, L.; Gettayacamin, M.; Lanteri, C.; Luong, T.; Melendez, V.; Moon, J.; Roncal, N.; Sousa, J.; Tangteung, A.; Wipf, P.; Dow, G. Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum Bioorg. Med. Chem. Lett. 2010, 20, 1347-1351
6. Dow, G.; Milner, E.; Bathurst, I; Bhonsle, J.; Caridha, D.; Gardner, S.; Gerena, L.; Kozar, M.; Lanteri, C.; Mannila, A.; McCalmont, W.; Melendez, V.; Moon, J.; Read, K.; Norval, S.; Roncal, N.; Shackleford, D.; Sousa, J.; Stouten, J.; White, K.; Zeng, Q.; Charman, S. Central nervous system (CNS) exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous (IV) dosing in mice Malar. J. 2011, 10, 150
7. Wipf, P.; Mo, T.; Geib, S.; Caridha, D.; Dow, G.; Gerena, L.; Roncal, N.; Milner, E. Synthesis and biological evaluation of the first pentafluorosulfanyl analogs of mefloquine Org. Biomol. Chem. 2009, 7, 4163-4165
8. Mo, T.; Milner, E.; Dow, G.; Wipf, P. Synthesis of 8-pentafluorosulfanyl analog of the antimalarial agent mefloquine Tetrahedron Lett. 2010, 51, 5137-5140
9. Initially (+)- and (-)-enantiomers of epoxide 3 were obtained via supercritical fluid chromatographic separation performed by Regis Technology (http://www.registech.com; refer to Supporting Information for chromatogram). Once a lead candidate was declared, the bulk synthesis of the corresponding (+) enantiomer of epoxide 3 was out-sourced to Bioblocks (http://www.bioblocks.com).
10. Dow, G.; Milner, E.; McCalmont, W. Next Generation Quinoline Methanols. PCT US0955796. September 2, 2009.
11. Milner, E. E.; Dow, G. S. 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against Plasmodium falciparum. Invention Disclosure Filed January 28, 2011.
12. Milner, E.; Sousa, J.; Pybus, B.; Melendez, V.; Gardner, S.; Grauer, K.; Moon, J.; Carroll, D.; Auschwitz, J.; Gettayacamin, M.; Lee, P.; Leed, S.; Norval, S.; Tungtaeng, A.; Zeng, Q.; Kozar, M.; D Read, K.; Li, Q.; Dow, G. Characterization of in vivo metabolites of WR319691, a novel compound with activity against Plasmodium falciparum. Eur. J. Drug Metab. Pharmacokinet. [Online early access]. Published Online: Jul 13, 2011.
13. United States Food and Drug Administration, Center for Drug Evaluation and Research. Development of New Stereoisomeric Drugs; United States Department of Health and Human Services: Washington, DC, 2005; http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/.
14. Hellgren, U.; Angel, V. H.; Bergvist, Y; Arvidsson, A.; Forero-Gomez, J. S.; Rombo, L. Plasma concentrations of sulfadoxine-pyrimethamine and of mefloquine during regular long term malaria prophylaxis Trans. R. Soc. Trop. Med. Hyg. 1990, 84, 46-49 (Pubitemid 20062549)
15. United States Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Healthy Volunteers; United States Department of Health and Human Services: Washington, DC, 2005; http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
16. The tables in the article were developed using SAR Vision software, info@chemapps.com.